566 related articles for article (PubMed ID: 17151111)
1. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
[TBL] [Abstract][Full Text] [Related]
2. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge.
Vanderzanden L; Bray M; Fuller D; Roberts T; Custer D; Spik K; Jahrling P; Huggins J; Schmaljohn A; Schmaljohn C
Virology; 1998 Jun; 246(1):134-44. PubMed ID: 9657001
[TBL] [Abstract][Full Text] [Related]
4. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
[TBL] [Abstract][Full Text] [Related]
5. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
[TBL] [Abstract][Full Text] [Related]
7. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors.
Meyer M; Yoshida A; Ramanathan P; Saphire EO; Collins PL; Crowe JE; Samal S; Bukreyev A
Cell Rep; 2018 Aug; 24(7):1816-1829. PubMed ID: 30110638
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
[TBL] [Abstract][Full Text] [Related]
9. Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses.
Liu M; Chen H; Luo F; Li P; Pan Q; Xia B; Qi Z; Ho WZ; Zhang XL
Vaccine; 2007 Sep; 25(36):6572-80. PubMed ID: 17675185
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.
Mellquist-Riemenschneider JL; Garrison AR; Geisbert JB; Saikh KU; Heidebrink KD; Jahrling PB; Ulrich RG; Schmaljohn CS
Virus Res; 2003 Apr; 92(2):187-93. PubMed ID: 12686428
[TBL] [Abstract][Full Text] [Related]
11. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
[TBL] [Abstract][Full Text] [Related]
12. Characterization of complex B cell epitopes on woodchuck hepatitis virus surface antigens by using plasmids encoding chimeric proteins and DNA immunization.
Zheng X; Schirmbeck R; Hilken G; Waters JA; Yang D; Reimann J; Roggendorf M; Lu M
Virology; 2002 Mar; 294(2):342-53. PubMed ID: 12009876
[TBL] [Abstract][Full Text] [Related]
13. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
[TBL] [Abstract][Full Text] [Related]
14. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.
Qiu X; Alimonti JB; Melito PL; Fernando L; Ströher U; Jones SM
Clin Immunol; 2011 Nov; 141(2):218-27. PubMed ID: 21925951
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of the highly pathogenic porcine reproductive and respiratory syndrome virus GP5 protein encoded by a synthetic ORF5 gene.
Li B; Xiao S; Wang Y; Xu S; Jiang Y; Chen H; Fang L
Vaccine; 2009 Mar; 27(13):1957-63. PubMed ID: 19368777
[TBL] [Abstract][Full Text] [Related]
17. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
18. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
19. Protective efficacy of neutralizing antibodies against Ebola virus infection.
Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
[TBL] [Abstract][Full Text] [Related]
20. The Role of Conserved N-Linked Glycans on Ebola Virus Glycoprotein 2.
Lennemann NJ; Walkner M; Berkebile AR; Patel N; Maury W
J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S204-9. PubMed ID: 26038399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
